Chemomab Therapeutics (CMMB) Accumulated Expenses (2018 - 2025)

Chemomab Therapeutics (CMMB) has 8 years of Accumulated Expenses data on file, last reported at $337000.0 in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Expenses fell 63.92% year-over-year to $337000.0; the trailing twelve-month figure through Dec 2025 stood at $337000.0 (down 63.92% YoY), and the FY2025 full-year result was $337000.0, down 63.92% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $337000.0, down from $464000.0 in the prior quarter.
• Across five years, Accumulated Expenses topped out at $3.4 million in Q4 2023 and bottomed at $337000.0 in Q4 2025.
• The 5-year median for Accumulated Expenses is $1.4 million (2022), against an average of $1.7 million.
• The widest annual swing landed in 2023, when Accumulated Expenses surged 375.08%; it then slumped 85.15% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $653000.0 in 2021, then jumped by 138.9% to $1.6 million in 2022, then soared by 119.42% to $3.4 million in 2023, then slumped by 72.71% to $934000.0 in 2024, then slumped by 63.92% to $337000.0 in 2025.
• The last three Accumulated Expenses figures came in at $337000.0 (Q4 2025), $464000.0 (Q3 2025), and $666000.0 (Q2 2025), per Business Quant data.

Peer Comparison